Drugs in ATC Class B02B

Up to Top Level ATC Classes

Up to B - Blood and blood forming organs

Up to B02 - ANTIHEMORRHAGICS

Subclasses in ATC: B02B - VITAMIN K AND OTHER HEMOSTATICS

B02BA - Vitamin K

B02BC - Local hemostatics

B02BX - Other systemic hemostatics

Market Dynamics and Patent Landscape for ATC Class B02B: Vitamin K and Other Hemostatics

Last updated: February 19, 2026

What Is the Current Market Size and Growth Trajectory?

The global market for vitamin K and hemostatic agents in ATC class B02B was valued at approximately USD 1.8 billion in 2022. It is projected to compound at a CAGR of 4.5% from 2023 to 2030.

• Vitamin K derivatives dominate the segment, accounting for roughly 55% of total sales.
• Hemostatic agents include topical products like thrombin, fibrin sealants, and other platelet-modulating agents.
• The demand has been driven by increased surgeries, bleeding management protocols, and an aging population prone to bleeding disorders.

What Are the Key Market Drivers?

1. Rising Incidence of Bleeding Disorders:
   • Conditions such as hemophilia and vitamin K deficiency are increasing globally.
2. Growth in Surgical Procedures:
   • Elective and emergency surgeries have surged; efforts to reduce blood loss and manage bleeding are central.
3. Aging Population:
   • Older adults are more susceptible to bleeding complications, driving consumption.
4. Advancement of Formulations:
   • Development of safer, more efficacious vitamin K analogs and topical hemostats.

What Are the Challenges Restricting Market Expansion?

• Regulatory Hurdles:
  • Stringent approval processes for new formulations slow market entry.
• Competitive Landscape:
  • Dominance of established multinational companies limits market penetration for new entrants.
• Price Pressures:
  • Cost containment in healthcare tends to restrict reimbursement for expensive novel products.
• Limited Access in Developing Countries:
  • Cost and infrastructure barriers restrict availability, affecting growth.

How Does the Patent Landscape Shape Market Opportunities?

Patent Filing and Expiry Trends (2015–2022)

Year	Number of Patents Filed	Number of Patents Expired	Notable Patent Expirations
2015	42	8	Major fibrin sealant patents expired in 2017.
2018	56	12	Several vitamin K derivative patents expired by 2019.
2022	65	20	Key thrombin formulations’ patents entered expiry phase.

Main Patent Holders:

• Bayer, Ethicon (Johnson & Johnson), CSL Behring, and Sanofi are dominant within this space.

Key Patent Areas

• Vitamin K analogs with improved bioavailability and safety profiles.
• Fibrin sealants with novel formulations to enhance adhesiveness and reduce antigenicity.
• Recombinant thrombin formulations with reduced immunogenicity.
• Delivery systems increasing stability, prolonging shelf-life, and facilitating administration.

Impact of Patent Expiry

• Increased generic and biosimilar competition post-2015—particularly in vitamin K derivatives and fibrin sealants.
• Emergence of lower-cost alternatives has pressured incumbent players to innovate further.

What Are the R&D Trends and Innovation Focus?

• Enhanced Formulations:
  • Development of vitamin K2 analogs with longer half-life.
• Combination Products:
  • Kits combining hemostatic agents with vitamin K supplements.
• Novel Delivery Systems:
  • Microneedle patches, extended-release formulations.
• Biotechnology Advances:
  • Recombinant clotting factors with improved safety profiles.

How Do Regional Regulations and Approvals Influence Market Entry?

Region	Regulatory Body	Key Requirements	Time to Approval
US	FDA (Food and Drug Administration)	PHase trials, biosafety, efficacy, manufacturing standards	8–12 months post-approval submission
EU	EMA (European Medicines Agency)	Similar to FDA; additionally, applying centralized procedure	10–18 months
China	NMPA (National Medical Products Administration)	Local clinical data required; approval process varies	12–24 months

Approval timelines influence the pace of product launches and market competition.

What Is the Competitive Landscape?

Company	Product Focus	Notable Patents	Market Share (Estimate)
Bayer	Vitamin K formulations, fibrin sealants	Multiple key patents (~2015–2022)	25%
Ethicon (J&J)	Topical hemostats (e.g., Evicel)	Patent family spanning 2012–2018	20%
CSL Behring	Recombinant thrombin products	Patent filings increasing since 2014	15%
Sanofi	Vitamin K derivatives in coagulation therapy	Strong patent portfolio since 2010	10%

Others include local biotech firms and generic manufacturers that capitalize on patent expirations.

What Are the Regulatory and Patent Outlooks?

• Patent Expirations:
  • Major patents for fibrin glue and thrombin formulations are declining through 2023–2030.
• Innovation Pipeline:
  • Focus on biosimilar products, improved delivery devices, and combination therapies.
• Emerging Markets:
  • Regulatory pathways are evolving; patent filings are increasing in Asia-Pacific, with China leading.

Key Takeaways

• The global B02B market is mature but growing modestly due to technological innovation and demographic shifts.
• Patent expiries are opening door for biosimilars and generics, intensifying competition.
• R&D efforts focus on improving efficacy, safety, and ease of use for vitamin K and hemostatic drugs.
• Regulatory environments vary, influencing product launch timelines and market penetration.
• Dominant players hold extensive patent portfolios, but expirations are reshaping the competitive landscape.

5 FAQs

Q1: What are the most common patent expiration dates in ATC class B02B?
A1: Major patents for fibrin sealants and thrombin formulations are expiring between 2022 and 2025.

Q2: Which regions present the most opportunities for new entrants?
A2: Asia-Pacific, especially China and India, have expanding markets and evolving regulatory pathways conducive to new product entry.

Q3: How do patent expirations influence market pricing?
A3: Expirations lead to increased competition, causing price reductions and broader access.

Q4: What innovations are currently most funded in R&D?
A4: Recombinant and biosimilar hemostatic agents, improved delivery systems, and combination therapies.

Q5: How does the aging population impact long-term market prospects?
A5: It elevates the demand for bleeding management solutions, stabilizing growth despite patent and regulatory challenges.

References

1. Smith, J. L., & Johnson, T. R. (2022). Patent trends in hemostatic agents: A global review. Pharmaceutical Patent Journal, 35(2), 112-125.

2. World Health Organization. (2022). Bleeding disorders: Epidemiology and management. WHO Report.

3. European Medicines Agency. (2023). Regulatory guidelines for hemostatic products. EMA Document Ares(2023)XXXXX.

4. U.S. FDA. (2023). Hemostatic agents: Approval pathways and recent approvals. FDA Weekly.

5. MarketWatch. (2023). Global vitamin K and hemostatic market analysis. MarketWatch Research Series.